Temporal Muscle Thickness Research Articles

Correlation of Temporal Muscle Thickness and Prognostic Nutritional Index with High-Grade Brain Tumor Progression

Correlation of Temporal Muscle Thickness and Prognostic Nutritional Index with High-Grade Brain Tumor Progression

Determination of masseter and temporal muscle thickness by ultrasound and muscle hardness by shear wave elastography in healthy adults as reference values.

The purpose of this study is to prospectively investigate the reference values of masseter and temporal muscle thicknesses by ultrasonography and muscle hardness values by shear wave elastography in healthy adults. The sample of the study consisted of a total of 160 healthy individuals aged between 18 and 59, including 80 women and 80 men. By examining the right and left sides of each participant, thickness and hardness values were obtained for 320 masseter muscles and 320 temporal muscles in total. The mean masseter muscle thickness was found to be 1.09 cm at rest and 1.40 cm in contraction. The mean temporal muscle thickness was found to be 0.88 cm at rest and 0.98 cm in contraction. The thickness values of the masseter and temporal muscles were significantly greater in the male participants than in the female participants (P < .001). While there were significant differences between the right and left masseter muscle thickness values at rest and in contraction, the values of the temporal muscles did not show a significant difference between the sides. While the resting hardness (rSWE) of the masseter muscle was transversally 6.91 kPa and longitudinally 8.49 kPa, these values in contraction (cSWE) were found, respectively, 31.40 and 35.65 kPa. The median temporal muscle hardness values were 8.84 kPa at rest and 20.43 kPa in contraction. Masseter and temporal muscle hardness values at rest and in contraction were significantly higher among the male participants compared to the female participants (P < .001). In this study, reference values for the thickness and hardness of the masseter and temporal muscles are reported. Knowing these values will make it easier to assess pain in the masseter and temporal muscles and determine the diagnosis and prognosis of masticatory muscle pathologies by allowing the morphological and functional assessments of these muscles, and it will identify ranges for reference parameters.

Changes in temporal muscle dimensions and their clinical impact in out-of-hospital cardiac arrest survivors

ObjectiveThis study investigates temporal muscle atrophy in out-of-hospital cardiac arrest patients post-resuscitation, seeking associations with neurological outcomes and factors associated with atrophy. MethodsUsing data from six Japanese intensive care units, adult patients’ post-resuscitation who underwent head computed tomography scans on admission and two to five days post-admission were assessed. Temporal muscle area, thickness, and density were quantified from a single cross-sectional image. Patients were categorized into 'atrophy' or 'no atrophy' groups based on median daily temporal muscle atrophy rates. The primary outcome was changes in temporal muscle dimensions between admission and follow-up two to five days later. Secondary outcomes included assessing the impact of temporal muscle atrophy on 30-day survival, as well as identifying any clinical factors associated with temporal muscle atrophy. ResultsA total of 185 patients were analyzed. Measurements at follow-up revealed significant decreases in temporal muscle area (214 vs. 191 mm2, p < 0.001), thickness (4.9 vs. 4.7 mm, p < 0.001), and density (46 vs. 44 HU, p < 0.001) compared to those at admission. The median daily rate for temporal muscle area atrophy was 2.0% per day. There was no significant association between temporal muscle atrophy and 30-day survival (hazard ratios, 0.71; 95% CI, 0.41–1.23, p = 0.231). Multivariable logistic regression found no clinical factors significantly associated with temporal muscle atrophy. ConclusionsTemporal muscle atrophy in post-resuscitation patients occurs rapidly at 2.0% per day. However, there was no significant association with 30-day mortality or any identified clinical factors. Further investigation into its long-term functional implications is warranted.

Frailty in Traumatic Brain Injury-The Significance of Temporal Muscle Thickness.

Temporal muscle thickness (TMT) on cranial CT scans has recently been identified as a prognostic imaging parameter for assessing a patient's baseline frailty. Here, we analyzed whether TMT correlates with Traumatic brain injury (TBI) severity and whether it can be used to predict outcome(s) after TBI. We analyzed the radiological and clinical data sets of 193 patients with TBI who were admitted to our institution and correlated the radiological data with clinical outcomes after stratification for TMT. Our analyses showed a significant association between high TMT and increased risk for intracranial hemorrhage (p = 0.0135) but improved mRS at 6 months (p = 0.001) as compared to patients with low TMT. Congruent with such findings, a lower TMT was associated with falls and reduced outcomes at 6 months (p < 0.0001 and p < 0.0001). High TMT was robustly associated with head trauma sequelae but was also associated with good clinical outcomes in TBI patients. These findings consolidate the significance of TMT as an objective marker of frailty in TBI patients; such measurements may ultimately be leveraged as prognostic indicators.

Sarcopenia and Hypoxia in Patients with Obstructive Sleep Apnea

Objectives. Obstructive sleep apnea (OSA) is associated with a variety of health issues. Both OSA and sarcopenia are associated with metabolic disorders; however, there is limited literature assessing the correlation between them. Therefore, we aimed to investigate sarcopenia using temporal muscle thickness (TMT) in patients with obstructive sleep apnea (OSA) and the association between sarcopenia and hypoxia. Methods. We enrolled patients with OSA and healthy controls. Both groups underwent brain magnetic resonance imaging (MRI) scans, including three-dimensional T1-weighted imaging. TMT, a marker for sarcopenia, was obtained based on the T1-weighted imaging and compared between the groups. Additionally, we analyzed the correlation between TMT and clinical factors in patients with OSA. Results. In total, 40 patients with OSA and 52 healthy controls were evaluated. There was no difference in TMT between patients with OSA and healthy controls ( 10.425 ± 2.13 vs. 10.400 ± 1.94 mm, p = 0.953 ). In the correlation analysis, age was negatively correlated with TMT ( r = − 0.356 , p = 0.023 ), and lowest oxygen saturation ( r = − 0.558 , p &lt; 0.001 ) in patients with OSA. Conclusion. Our results demonstrated negative correlations between TMT and lowest oxygen saturation in the patients with OSA. These findings suggest potential relationships between sarcopenia and hypoxia in patients with OSA. Thus, these results underline the importance of maintaining oxygen saturation in patients with OSA by implementing active treatment. This study also demonstrates the feasibility of sarcopenia assessment by measuring TMT through conventional head MRI in patients with various neurological disorders.

Correlation between temporal muscle thickness and grip strength in hemiplegic patients with acute stroke

Correlation between temporal muscle thickness and grip strength in hemiplegic patients with acute stroke

NIMG-34. TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSED MGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS

Abstract BACKGROUND In cranial MRI assessed temporal muscle thickness (TMT) correlates with lumbar skeletal muscle mass, which serves as surrogate marker of sarcopenia. Prior research has identified TMT as a prognostic marker in glioblastoma. However, incorporation into clinical practice is challenging due to the heterogeneity of previous studies and the absence of established cutoff values. To address this, we conducted a multicenter analysis to validate recently proposed sex-specific cutoff values in a homogeneous real-life cohort of newly diagnosed MGMT promoter-methylated glioblastoma patients uniformly treated with combined CCNU/temozolomide. We implemented a balanced control cohort for comparison. METHODS TMT was measured at baseline using preoperative or early postoperative MRI and in the disease course using the first MRI after completion of radiotherapy. Patients were TMT-based divided into “at risk of sarcopenia” or “normal muscle status”. Kaplan-Meier statistics and multivariable Cox regression analysis were used for correlation with survival. RESULTS In total, n = 126 patients were analyzed (n = 66 received CCNU/temozolomide; n = 60 received temozolomide). Patients with normal muscle mass at baseline (&amp;gt; 6,3 mm for men; &amp;gt; 5,2 mm for women) had significantly prolonged mOS (44.3 versus 16.7 months for CCNU/temozolomide; 29.5 versus 17.4 months for temozolomide) compared to those at risk of sarcopenia. In a multivariable Cox regression analysis, normal muscle mass (HR: 0.39, 95% CI: 0.23-0.66; p = 0.0003) and age at diagnosis of &amp;lt; 50 years (HR: 0.42, 95% CI: 0.22-0.79; p = 0.0067) were significant prognostic markers. Longitudinally, survival was best in patients with lack of TMT decline. CONCLUSIONS This analysis suggests TMT to serve as a prognostic marker in glioblastoma patients treated with CCNU/temozolomide or with temozolomide. However, for TMT assessment to be implemented in a generalizable manner, such as for patient selection for therapeutic measures, further validation in prospective controlled trials is necessary.

The relationship between temporal muscle thickness and triglyceride glucose index in sarcopenia with mortality and third-month functional outcomes in patients after acute stroke.

Especially in recent years, temporal muscle thickness has been used as an important parameter for sarcopenia in neurological disorders. In addition, triglyceride glucose index was evaluated separately in studies conducted in terms of coronary diseases, diabetes, high blood pressure, body mass index and acute stroke. In this clinical study, unlike the others, both temporal muscle thickness and triglyceride glucose index were evaluated together in acute stroke patients in terms of sarcopenia. We aimed to investigate the relationship between temporal muscle thickness and triglyceride glucose index, which is atherosclerotic index, with mortality and 3rd month functional outcomes in acute stroke patients. In this retrospective study, 147 patients admitted to Ankara City Hospital with the diagnosis of acute ischemic stroke between January 2021 and September 2022 were evaluated. Fasting triglyceride glucose indexes of the patients were calculated. The temporal muscle thickness measurement of the patients was performed by the radiologist using computed tomography images. Those who scored 3 or higher on the modified Rankin Scale (mRS) at the third month were considered to have poor functional outcome. A significant cutoff point was found for estimating mortality for the temporal muscle thickness parameter [area under the curve for a receiver operating characteristic curve (AUC) = 0.636; P = .012]. The cutoff point was obtained as ≤ 5.2. Sensitivity value was 65%, specificity value was 65%, the positive predictive value (PPV) value was 42.62% and the negative predictive value (NPV) value was 82.28%. Similarly, for the triglyceride glucose index parameter, there was a significant cutoff point in estimating mortality (AUC = 0.673; P = .003). The cutoff point was obtained as ≥ 8.23. Sensitivity value was 91.18%, specificity value was 13%, PPV value was 26.96% and NPV value was 81%. Temporal muscle thickness and triglyceride glucose index parameters were found to be statistically important parameters of sarcopenia. It was concluded that the evaluation of these 2 parameters in terms of both mortality and sarcopenia in acute stroke patients is important in the evaluation of neurological and cardiac disorders.

Frailty in cerebellar ischemic stroke-The significance of temporal muscle thickness.

While comprising only 2% of all ischemic strokes, cerebellar strokes are responsible for substantial morbidity and mortality due to their subtle initial presentation and the morbidity of posterior fossa swelling. Furthermore, low temporal muscle thickness (TMT) has recently been identified as a prognostic imaging parameter to assess patient frailty and outcome. We analyzed radiological and clinical data sets of 282 patients with cerebellar ischemic stroke. Our analysis showed a significant association between low TMT, reduced NIHSS and mRS at discharge (p = 0.035, p = 0.004), and reduced mRS at 12 months (p = 0.001). TMT may be used as a prognostic imaging marker and objective tool to assess outcomes in patients with cerebellar ischemic stroke.

The relationship between temporal muscle thickness and disease activity in Cushing's disease.

This study aimed to investigate the relationship between hypercortisolism and temporal muscle thickness (TMT) in Cushing's disease (CD). A retrospective review of medical records was conducted for patients with CD who presented to our clinic between 2012 and 2022. Biochemical data and TMT measurements from sella imaging were evaluated during diagnosis and the first postoperative year. A total of 44 patients were included in the study, with an average age of 43.9years, of which 38 were female. The mean TMT at the time of diagnosis was 19.07 ± 1.71mm, with no significant difference between males and females (p = 0.097), and no correlation between the TMT and age at diagnosis (p = 0.497). There was an inverse relationship between TMT and serum cortisol levels, 24-h UFC, and midnight salivary cortisol at the time of diagnosis of CD (p < 0.05, for all). One year after surgery, TMT significantly increased in all patients compared to baseline (p < 0.001). Furthermore, patients who achieved postoperative remission had significantly higher TMT values compared to those who did not achieve remission (p = 0.043). Among the patients who achieved remission, those who achieved remission through surgery had significantly higher TMT compared to those who could not reach remission with surgery and patients who started medical treatment and achieved biochemical remission (p = 0.01). Patients with severe myopathy and sarcopenia had significantly lower TMT values than the others (p < 0.001). Temporal muscle thickness was found to be associated with disease activity and disease control in Cushing's disease.

Advances in the relationship between temporal muscle thickness and prognosis of patients with glioblastoma: a narrative review.

The most dangerous variety of glioma, glioblastoma, has a high incidence and fatality rate. The prognosis for patients is still bleak despite numerous improvements in treatment approaches. We urgently need to develop clinical parameters that can evaluate patients' conditions and predict their prognosis. Various parameters are available to assess the patient's preoperative performance status and degree of frailty, but most of these parameters are subjective and therefore subject to interobserver variability. Sarcopenia can be used as an objective metric to measure a patient's physical status because studies have shown that it is linked to a bad prognosis in those with cancers. For the purpose of identifying sarcopenia, temporal muscle thickness has demonstrated to be a reliable alternative for a marker of skeletal muscle content. As a result, patients with glioblastoma may use temporal muscle thickness as a potential marker to correlate with the course and fate of their disease. This narrative review highlights and defines the viability of using temporal muscle thickness as an independent predictor of survival in glioblastoma patients, and it evaluates recent research findings on the association between temporal muscle thickness and prognosis of glioblastoma patients.

P11.65.B TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSEDMGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS

Abstract BACKGROUND In cranial magnetic resonance imaging (MRI) assessed temporal muscle thickness (TMT) correlates with lumbar skeletal muscle mass, which serves as a surrogate marker of sarcopenia. Prior research has identified TMT as a prognostic marker in glioblastoma. However, incorporation into clinical practice is challenging due to the heterogeneity of previous studies and the absence of established cutoff values. To address this, we conducted a multicenter analysis to validate recently proposed sex-specific cutoff values in a homogeneous cohort of newly diagnosed MGMT promoter-methylated glioblastoma patients uniformly treated under real-life conditions with combined CCNU/temozolomide. We also included a balanced control cohort for comparison. MATERIAL AND METHODS TMT was measured at baseline using initial preoperative and postoperative MRI and during the course of the disease using the first MRI after completion of radiotherapy in the first therapy-line. Using TMT and previously reported cutoff values from the literature, patients were classified into "at risk of sarcopenia" or "normal muscle status" cohorts. To correlate TMT with survival, we conducted Kaplan-Meier and multivariable Cox regression analyses. RESULTS A total of 126 patients were analyzed, with 66 patients treated with combined CCNU/temozolomide and 60 patients treated with temozolomide single-drug treatment. In both cohorts, patients with normal muscle mass at baseline had significantly longer survival. Specifically, in the CCNU/temozolomide cohort median progression-free survival (mPFS) was 16.7 months in the normal muscle mass group versus 6.8 months in the at-risk group (p=0.0008); median overall survival (mOS) was 44.2 months in the normal muscle mass group versus 16.7 months in the at-risk group (p=0.0046). In the temozolomide single-drug cohort, mPFS was 12.4 months in the normal muscle mass group versus 7.7 months in the at-risk group, and mOS was 29.5 months in the normal muscle mass group versus 17.4 months in the at-risk group (p=0.0006). Using multivariable Cox regression analysis, we found normal muscle mass (HR: 0.39, 95% CI: 0.23-0.66; p=0.0003) and initial age at diagnosis of less than 50 years (HR: 0.42, 95% CI: 0.22-0.79; p=0.0067) were statistically significant prognostic markers. Longitudinally, patients with lacking TMT decline during the course of the disease had the best survival outcomes. CONCLUSION This analysis suggests TMT to serve as a prognostic marker in glioblastoma patients treated with CCNU/temozolomide or single-drug treatment with temozolomide. However, for TMT assessment to be implemented in a generalizable manner, such as for patient selection for therapeutic measures, further validation in prospective controlled trials is necessary.

P20.11.A TEMPORAL MUSCLE THICKNESS AS PROGNOSTIC MARKER IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA - A VALIDATION STUDY

Abstract BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare, aggressive diffuse large B-cell lymphoma, confined to the central nervous system. Age and performance status are validated prognostic variables in PCNSL. Frailty may also be a factor but is not easily quantified. Temporal muscle thickness (TMT), as parameter of sarcopenia, is believed to reflect frailty, is easily measurable and may be a valuable additional prognostic factor: mean TMT has been described as an independent prognostic factor in PCNSL patients. This study aims to validate these results in a prospective cohort. MATERIAL AND METHODS All patients from a large phase III trial (HOVON 105/ALLG NHL 24; EudraCT 2009-014722-42) of whom baseline axial T1 weighted magnetic resonance images (MRI) were available were included. Sarcopenia is defined as a mean TMT &amp;lt;6.3mm for men and &amp;lt;5.2mm for women, measured on axial T1-weighted MRI. The TMT was measured by a radiologist (RG) with and a neurologist (MvdM) without correction for angulation of images. Sarcopenia, together with known other prognostic factors were analyzed in a Cox-regression analysis for progression-free (PFS) and overall survival (OS) for both investigators. RESULTS TMT measurements were possible in 164/199 trial patients. The median mean TMT was 7.62mm (IQR: 6.58-9.00; measured by RG) and 5.94mm (IQR: 5.09-7.01; measured by MvdM). The mean TMT was not significantly different between those who used dexamethasone, and those who did not. Sarcopenia was present in 75 patients (46%), measured by MvdM without correction for angulation of the images and in 21 patients (13%), measured by RG with correction for angulation of the images. In univariate analyses, age (&amp;gt;60 years-old) and baseline Mini-Mental State Examination-score &amp;lt;27 were significantly associated with adverse PFS and OS. In multivariate analyses, only age remained as independent prognostic factor for adverse PFS and OS. Sarcopenia, as measured by either of the investigators, was not associated with survival. For measurements by RG, presumed to be most accurate, the Hazard Ratio (95% confidence interval) was 0.68 (0.33-1.40), p=0.30 for PFS, and HR (95% CI): 0.97 (0.42-2.20), p=0.93 for OS in the multivariate analysis. CONCLUSION There was a low interobserver agreement between a neurologist and a radiologist regarding TMT measurements, which questions the use of this parameter in daily practice by non-radiologists. Sarcopenia, based on the mean TMT, was not a prognostic factor in PCNSL patients for PFS and OS. The small number of patients with sarcopenia in this series may have influenced results.

The relation of sarcopenia and disability in multiple sclerosis.

The relation of sarcopenia and disability in MS is unknown. To investigate the relation of temporal muscle thickness (TMT) and disability. A cohort of 132 people who presented with a clinically isolated syndrome (CIS) suggestive of MS at a mean age of 30.0 years, were prospectively followed clinically and with MRI over 30-years. TMT and expanded disability status scale (EDSS) were assessed at baseline, one- five- ten- fourteen- twenty- and thirty-year follow-up. At 30-years, 27 participants remained classified as having had a CIS, 34 converted to relapsing remitting MS, 26 to secondary progressive MS, and 16 had died due to MS. Using linear mixed effect models with subject nested in time, greater annualized TMT-thinning was seen in individuals who developed MS (-0.04mm/a, 95%CI: -0.07 to -0.01, p=0.023). In those who converted to MS, a thinner TMT was reached at 14- (p=0.008), 20- (p=0.002) and 30-years (p< 0.001). TMT was negatively correlated with EDSS at 20-years (R=-0.18, p=0.032) and 30-years (R-0.244, p=0.005). Longitudinally, TMT at earlier timepoints was not predictive for 30-year clinical outcomes. TMT thinning is accelerated in MS and correlated with disability in later disease stages, but is not predictive of future disability.

Temporal muscle thickness has no prognostic relevance in patients with high-grade glioma compared to functional scales.

GBM research is constantly assessing potential valuable prognostic biomarkers to better understand the disease and prognosticate future outcomes. Measuring temporal muscle thickness (TMT) has appeared to be a promising new surrogate marker for skeletal muscle mass and sarcopenia, which further indicates frailty and predicts overall survival (OS). The aim of this study was to determine its usefulness as a prognostic marker in patients with high-grade glioma compared to functional status scales. TMT was measured in preoperative axial T1-weighted contrast-enhanced magnetic resonance images in 277 patients who received surgical treatment of newly diagnosed WHO III and IV gliomas in our institution between 2015 and 2020. Clinical Frailty Scale (CFS) and Karnofsky Performance Scale (KPS) were assessed preoperatively and during a follow-up visit. Female gender has shown significant correlation with TMT, while TMT did not correlate with preoperative and follow-up functional scores, age, WHO classification, IDH mutation, MGMT promoter methylation, EGFR and ATRX expression, or 1p/19q co-deletion. No significant prognostic value of TMT could be shown in 6, 12, and 24 months OS, while changes in CFS and KPS proved to have a significant impact. Only female gender, but no other clinical, histological, or molecular marker showed any interrelation with TMT. Functional scores outclass measuring TMT as a reliable prognostic factor for predicting OS in patients with high-grade glioma.

Initial Temporal Muscle Thickness and Area: Poor Predictors of Neurological Outcome in Aneurysmal Subarachnoid Hemorrhage in a Central European Patient Cohort.

The temporalis muscle area (TMA) has been proclaimed as a surrogate parameter for estimating skeletal muscle mass. Pilot studies in Asian populations suggested temporal muscle thickness (TMT) and TMA as prognostic factors for neurological outcomes in aneurysmal subarachnoid hemorrhage (aSAH) patients. This study aimed to validate these findings in a larger European patient cohort. We retrospectively analyzed age, sex, aneurysm location, treatment, World Federation of Neurosurgical Societies (WFNS) grade, Fisher score, and modified Rankin Score (mRS) at six months in patients with aSAH. TMT and TMA measurements were obtained from initial native CT scans. Logistic regression with the dichotomized six-month mRS as the outcome incorporating TMT, weighted average of TMT, or TMA as predictors was performed. Of the included 478 patients, 66% were female, the mean age was 56, and 48% of patients had an mRS of three to six after six months. The mean TMT at the level of the Sylvian fissure was 5.9 (±1.7) mm in males and 4.8 (±1.8) mm in females. The mean TMA was 234.5 (±107.9) mm2 in females and 380 (±134.1) mm2 in males. WFNS grade (p < 0.001), Fisher score (p < 0.001), and age (p < 0.05) correlated significantly with the mRS after six months. No correlation was found between mRS after six months and the TMT at the Sylvian fissure (p = 0.3), the weighted average of TMT (p = 0.1), or the TMA (p = 0.1). In this central European patient cohort of 478 individuals, no significant associations were found between TMT/TMA and neurological outcomes following aSAH. Further prospective studies in diverse patient populations are necessary to determine the prognostic value of TMA and TMT in aSAH patients.

Temporalis and masseter muscle thickness as predictors of post-stroke dysphagia after endovascular thrombectomy

PurposePost-stroke dysphagia (PSD) is a common sequela of stroke. Given the association between dysphagia and sarcopenia, we aimed to investigate the association between PSD and temporal muscle thickness (TMT) and masseter muscle thickness (MMT) following endovascular thrombectomy (EVT) in patients with large-vessel occlusion (LVO). MethodsThis retrospective cohort study included hospitalized patients with LVO stroke who underwent EVT between January 1, 2018, and October 31, 2022. TMT and MMT were measured using brain computed tomography (CT) angiography. The correlation between relevant clinicodemographic factors and both TMT and MMT was examined. The relationship between each of two parameters (TMT and MMT) and PSD, which was defined as the retention of the nasogastric (NG) tube at 4 and 12 weeks, was evaluated in adjusted logistic regression models. ResultsAmong the 148 participants, the mean TMT and MMT was 5.9 ± 1.6 and 11.2 ± 2.3 mm, respectively. Lower age, male sex, higher body mass index (BMI), higher albumin levels, and a lower initial National Institute of Health Stroke Scale (NIHSS) score were associated with higher TMT and MMT (p < 0.05). In the logistic regression analysis adjusted for age, sex, BMI, serum albumin, and NIHSS score, lower TMT and MMT significantly correlated with PSD at weeks 4 and 12 (p < 0.001). ConclusionTMT and MMT are associated with age, sex, BMI, albumin, and the initial NIHSS score. Both TMT and MMT are independent indicators of post-EVT PSD in stroke patients and serve as reliable predictors of NG removal.

Association of Temporalis Muscle Mass with Early Cognitive Impairment in Older Patients with Acute Ischemic Stroke.

The prognostic value of temporal muscle mass has been studied in various neurological disorders. Herein, we investigated the association between temporal muscle mass and early cognitive function in patients with acute ischemic stroke. This study included 126 patients with acute cerebral infarction aged ≥65 years. Temporal muscle thickness (TMT) was measured using T2-weighted brain magnetic resonance imaging at admission for acute stroke. Within 2 weeks of stroke onset, skeletal mass index (SMI) and cognitive function were assessed using bioelectrical impedance analysis and the Korean version of the Montreal Cognitive Assessment (MoCA), respectively. Pearson's correlation analyzed the correlation between TMT and SMI, and multiple linear regression analyzed independent predictors of early post-stroke cognitive function. TMT and SMI were significantly positively correlated (R = 0.36, p < 0.001). After adjusting for covariates, TMT was an independent predictor of early post-stroke cognitive function, stratified by the MoCA score (β = 1.040, p = 0.017), age (β = -0.27, p = 0.006), stroke severity (β = -0.298, p = 0.007), and education level (β = 0.38, p = 0.008). TMT may be used as a surrogate marker for evaluating skeletal muscle mass because it is significantly associated with post-stroke cognitive function during the acute phase of ischemic stroke; therefore, TMT may help detect older patients at a high risk of early post-stroke cognitive impairment.

Is sarcopenia a predictor of overall survival in primary IDH-wildtype GBM patients with and without MGMT promoter hypermethylation?

Background: In this study, we aimed to examine the success of temporal muscle thickness (TMT) and masseter muscle thickness (MMT) in predicting overall survival (OS) in primary IDH-wild glioblastoma (GBM) patients with and without MGMT promoter hypermethylation through publicly available datasets. Methods: We included 345 primary IDH-wild GBM patients with known MGMT promoter hypermethylation status who underwent gross-total resection and standard treatment, whose data were obtained from the open datasets. TMT was evaluated on axial thin section postcontrast T1-weighted images, and MMT was evaluated on axial T2-weighted images. The median TMT and MMT were used to determine the cut-off point. Results: The findings showed that median TMT 9.5 mm and median MMT 12.7 mm determined the cut-off value in predicting survival. Both TMT and MMT values less than the median muscle thickness were negatively associated with OS (TMT&lt;9.5: HR 3.63 CI 2.34–4.23, p &lt;0.001, MMT&lt;12.7: HR 3.53 CI 2.27–4.07, p &lt;0.001). When patients were classified according to MGMT positivity, the findings showed MGMT-negative patients (TMT&lt;9.5: HR 2.54 CI 1.89–3.56, p &lt;0.001, MMT&lt;12.7: HR 2.65 CI 2.07–3.62, p &lt;0.001) and MGMT-positive patients (TMT&lt;9.5: HR 3.84 CI 2.48–4.28, p &lt;0.001, MMT&lt;12.7: HR 3.73 CI 2.98–4.71, p &lt;0.001). Conclusion: Both TMT and MMT successfully predict survival in primary GBM patients. In addition, it can successfully predict survival in patients with and without MGMT promoter hypermethylation.

Temporal Muscle Thickness Correlates with Sarcopenia in Parkinson's Disease.

Sarcopenia is characterized by a progressive loss of muscle mass, strength, and function resulting in adverse health outcomes. Current assessment strategies are bothersome and means to simplify the diagnosis are an unmet medical need in Parkinson's disease (PD). To evaluate temporal muscle thickness (TMT) obtained on routine cranial MRI as a surrogate marker of sarcopenia in PD patients. We correlated TMT from axial non-contrast-enhanced T1-weighted sequences of MRI close (±12 months) to an outpatient visit including sarcopenia (EWGSOP1, EWGSOP2, SARC-F), frailty (Fried's criteria, clinical frailty scale), and disease characteristics of Parkinson's patients (Hoehn and Yahr-scale, Movement Disorder Society-Unified Parkinson's Disease Rating Scale, quality of life with the Parkinson's Disease Questionnaire-8) assessments. Cranial MRI was available in 32 patients with a mean age of 73.56±5.14 years, mean disease duration of 11.46±5.66 years, and median Hoehn and Yahr stage of 2.5. The mean TMT was 7.49±2.76 (7.15) mm. Mean TMT was significantly associated with sarcopenia (EWGSOP2, p = 0.018; EWGSOP1, p = 0.023) and frailty status (physical phenotype; p = 0.045). Moreover, there were significant moderate to strong correlations between TMT measurement and appendicular skeletal muscle mass index (r: 0.437, p = 0.012), as well as handgrip strength (r: 0.561, p < 0.001). Reduced TMT seems to be a promising surrogate marker for sarcopenia (EWGSOP2) and muscle strength in this pilot study in PD patients.